Trade Amicus Therapeutics Inc - FOLD CFD

Amicus Company profile

About Amicus Therapeutics, Inc.

Amicus Therapeutics, Inc. is a global biotechnology company that is focused on discovering, developing, and delivering medicines for rare diseases. The Company’s portfolio is Galafold (migalastat), which is the approved oral precision medicine for people living with Fabry disease. Migalastat is approved under the trade name Galafold in the United States, European Union, United Kingdom and Japan. Its biologics program in its pipeline is Amicus Therapeutics GAA (AT-GAA), which is a clinical-stage treatment paradigm for Pompe disease. The United States Food and Drug Administration (FDA) granted Breakthrough Therapy designation (BTD) to AT-GAA for the treatment of late onset Pompe disease. Its pipeline includes gene therapy programs in rare, neurologic lysosomal disorders (LDs), specifically: CLN6, CLN3 and CLN1 Batten disease, Pompe disease, Fabry disease, CDKL5 deficiency disorder (CDD), Mucopolysaccharidosis Type IIIB (MPS IIIB), as well as in Mucopolysaccharidosis Type IIIA (MPS IIIA).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Amicus Therapeutics, Inc. revenues increased 17% to $305.5M. Net loss decreased 10% to $250.5M. Revenues reflect Ex-US segment increase of 16% to $210.1M, U.S segment increase of 19% to $95.4M. Lower net loss reflects Research and development - Balancing val decrease of 11% to $254.7M (expense), Loss on exchange of convertible notes decrease from $7.3M (expense) to $0K.

Equity composition

Common Stock, $.01 Par, 04/11, 50M auth., 34,508,932 issd. Insider's own 20.53%. IPO: 5/31/07, 5M shs. @ $15 by Morgan Stanley & Co. Incorporated, Merrill Lynch, Pierce, Fenner & SmithInc.